Skip to main content
You are using an older version of Internet Explorer that is not supported by Please upgrade for the best experience.

Suresh Mohan, M.D.


Originally from Ann Arbor, Michigan, Dr. Suresh Mohan graduated from the University of Michigan with dual concentrations in music and cell and molecular biology. When not pursuing a cappella fame, he studied protein-trafficking in macrophage phagocytosis using FRET (Fluorescence resonance energy transfer) imaging and live-cell microscopy. He went on to complete his medical training at the Warren Alpert Medical School of Brown University and spent one year at the NIDCD (National Institute on Deafness and Other Communication Disorders) investigating novel targeted chemotherapeutics for head and neck squamous cell carcinoma. Dr. Mohan completed his general surgery internship at Brigham and Women’s Hospital and is currently pursing the seven-year T32 research track in his residency program.

For more information on Dr. Mohan, check out his Harvard Catalyst website and Google Scholar page.


Undergraduate School
University of Michigan (Music, Cell and Molecular Biology)

Medical School
Warren Alpert Medical School of Brown University


SMAC mimetic birinapant plus radiation eradicates human head and neck cancers with genomic amplifications of cell death genes FADD and BIRC2. Eytan DF, Snow GE, Carlson S, Derakhshan A, Saleh A, Schiltz S, Cheng H, Mohan S, Cornelius S, Coupar JF, Sowers AL, Hernandez L, Mitchell JB, Annunziata CM, Chen Z, Van Waes C. Cancer Res. 2016 Jul 28.
PMID: 27469115

Papillary thyroid cancer in a child with progressive transformation of germinal centers: A case report. Mohan S, Denardo B, Stachurski D, Greene Welch J, Groblewski JC. Case Rep Otolaryngol. 2016. 2016:6469073.
PMID: 27069706

Ossifying Parotid Carcinoma ex pleomorphic adenoma. Mohan S, Puram SV, Yarlagadda B, Deschler, DG. Case Rep Otolaryngol. 2015. 2015:395358.

MEK inhibitor PD-0325901 overcomes resistance to PI3K/mTOR inhibitor PF-5212384 and potentiates anti-tumor effects in human head and neck squamous cell carcinoma. Mohan S, Vander Broek RJ, Shah S, Eytan DF, Pierce ML, Carlson SG, Chen Z, Van Waes C. Clin Cancer Res. 2015 May 14. 

MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer. Bian Y, Han J, Kannabiran V, Mohan S, Cheng H, Friedman J, Zhang L, Van Waes C, Chen Z. Int J Biol Sci. 2015 Feb 23. 11(4):411-22.

A case of trigeminocardiac reflex during infrastructure maxillectomy. Mohan S, Flis DW, O'Leary MA. JAMA Otolaryngol Head Neck Surg. 2014. 140(6):563-564.

The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, crosstalk, and therapies. Vander Broek R, Mohan S, Eytan DF, Chen Z, Van Waes C. Oral Dis. 2013 Nov 12. 53.

A Cdc42 activation cycle coordinated by PI 3-kinase during Fc receptor-mediated phagocytosis. Beemiller P, Zhang Y, Mohan S, Levinsohn E, Gaeta I, Hoppe AD, Swanson JA. Mol Biol Cell. 2010. 21(3):470–80.

A complete list of research publications can be seen at